WO2006073771A3 - Polyethylene glycol linked mc4r or mc3r agonist peptides - Google Patents

Polyethylene glycol linked mc4r or mc3r agonist peptides Download PDF

Info

Publication number
WO2006073771A3
WO2006073771A3 PCT/US2005/045867 US2005045867W WO2006073771A3 WO 2006073771 A3 WO2006073771 A3 WO 2006073771A3 US 2005045867 W US2005045867 W US 2005045867W WO 2006073771 A3 WO2006073771 A3 WO 2006073771A3
Authority
WO
WIPO (PCT)
Prior art keywords
mc4r
agonist peptides
polyethylene glycol
mc3r agonist
mc3r
Prior art date
Application number
PCT/US2005/045867
Other languages
French (fr)
Other versions
WO2006073771A2 (en
Inventor
David Benjamin Flora
John Philip Mayer
Liang Zeng Yan
Original Assignee
Lilly Co Eli
David Benjamin Flora
John Philip Mayer
Liang Zeng Yan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, David Benjamin Flora, John Philip Mayer, Liang Zeng Yan filed Critical Lilly Co Eli
Publication of WO2006073771A2 publication Critical patent/WO2006073771A2/en
Publication of WO2006073771A3 publication Critical patent/WO2006073771A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention provides MC4R or MC3R agonist peptides coupled to at least one polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide. These PEGylated MC4R or MC3R agonist peptides and compositions are useful in treating obesity, diabetes, sexual dysfunction, cachexia, sarcopenia, dyslipidemia, to increase weight loss, or to increase muscle mass.
PCT/US2005/045867 2005-01-05 2005-12-16 Polyethylene glycol linked mc4r or mc3r agonist peptides WO2006073771A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64221905P 2005-01-05 2005-01-05
US60/642,219 2005-01-05

Publications (2)

Publication Number Publication Date
WO2006073771A2 WO2006073771A2 (en) 2006-07-13
WO2006073771A3 true WO2006073771A3 (en) 2007-03-29

Family

ID=36647979

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/045867 WO2006073771A2 (en) 2005-01-05 2005-12-16 Polyethylene glycol linked mc4r or mc3r agonist peptides

Country Status (1)

Country Link
WO (1) WO2006073771A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877890B2 (en) 2009-11-23 2014-11-04 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic peptides
US8933194B2 (en) 2009-11-23 2015-01-13 Palatin Technologies, Inc. Melanocortin-1 receptor-specific linear peptides

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1893240A2 (en) * 2005-06-13 2008-03-05 Nastech Pharmaceutical Company Inc. Transmucosal delivery of peptide derivatives
KR101232201B1 (en) 2005-07-08 2013-02-12 입센 파마 에스.에이.에스 Melanocortin receptor ligands
WO2009152079A1 (en) 2008-06-09 2009-12-17 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for treatment of sexual dysfunction
UY32690A (en) 2009-06-08 2011-01-31 Astrazeneca Ab SPECIFIC PEPTIDES FOR MELANOCORTIN RECEPTORS

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000033658A1 (en) * 1998-12-09 2000-06-15 Eleanor Roosevelt Institute Composition and method for regulation of body weight and associated conditions
WO2000058361A1 (en) * 1999-03-29 2000-10-05 The Procter & Gamble Company Melanocortin receptor ligands
WO2004099246A2 (en) * 2003-05-09 2004-11-18 Novo Nordisk A/S Peptides for use in treating obesity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000033658A1 (en) * 1998-12-09 2000-06-15 Eleanor Roosevelt Institute Composition and method for regulation of body weight and associated conditions
WO2000058361A1 (en) * 1999-03-29 2000-10-05 The Procter & Gamble Company Melanocortin receptor ligands
WO2004099246A2 (en) * 2003-05-09 2004-11-18 Novo Nordisk A/S Peptides for use in treating obesity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MAYER JOHN P ET AL: "Discovery of a beta-MSH-derived MC-4R selective agonist.", JOURNAL OF MEDICINAL CHEMISTRY. 5 MAY 2005, vol. 48, no. 9, 5 May 2005 (2005-05-05), pages 3095 - 3098, XP002407729, ISSN: 0022-2623 *
YAN LIANG Z ET AL: "Potent and selective MC-4 receptor agonists based on a novel disulfide scaffold.", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS. 15 OCT 2005, vol. 15, no. 20, 15 October 2005 (2005-10-15), pages 4611 - 4614, XP002407728, ISSN: 0960-894X *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877890B2 (en) 2009-11-23 2014-11-04 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic peptides
US8933194B2 (en) 2009-11-23 2015-01-13 Palatin Technologies, Inc. Melanocortin-1 receptor-specific linear peptides
US9447148B2 (en) 2009-11-23 2016-09-20 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic peptides
US9580466B2 (en) 2009-11-23 2017-02-28 Palatin Technologies, Inc. Melanocortin-1 receptor-specific linear peptides

Also Published As

Publication number Publication date
WO2006073771A2 (en) 2006-07-13

Similar Documents

Publication Publication Date Title
WO2005091944A3 (en) Glycol linked fgf-21 compounds
WO2006073771A3 (en) Polyethylene glycol linked mc4r or mc3r agonist peptides
HRP20050683A2 (en) Polyethylene glycol linked glp-1 compounds
WO2006081249A3 (en) Conjugates of biologically active proteins having a modified in vivo half-life
WO2006010057A3 (en) Therapeutic peptides
ME02786B (en) Glp-1 pegylated compounds
WO2006053299A3 (en) Site-directed modification of fviii
WO2006023356A3 (en) Selective vpac2 receptor peptide agonists
WO2007035716A3 (en) Compositions comprising receptor-associated protein (rap) variants specific for cr-containing proteins and uses thereof
WO2003011115A3 (en) Peptide-based multimeric targeted contrast agents
WO2004089396A3 (en) Anti-fungal peptidomimetics
WO2007030761A3 (en) Acyclic 1,4-diamines and uses thereof
WO2005030797A3 (en) Melanocortin receptor agonists
UA96418C2 (en) Use of peptides that bind to a tpo receptor
WO2008147556A3 (en) Melanocortin receptor ligands modified with hydantoin
WO2005076696A3 (en) Pneumolysin derivatives
WO2005042027A3 (en) Antagonists of the bradykinin b1 receptor
WO2007101146A3 (en) Selective vpac2 receptor peptide agonists
TW200517103A (en) Peptides and compounds that bind to a receptor
IL175646A0 (en) Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof
WO2005092362A3 (en) Pharmaceutical combined preparation containing a therapeutic protein
WO2005072766A3 (en) Peptides that bind to hsp90 proteins
WO2007018879A3 (en) Interferon-gamma antagonists and therapeutic uses thereof
ZA200800457B (en) Novel biologically active peptides and their new uses
IL156263A0 (en) Livin-derived peptides, compositions and uses thereof

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05854555

Country of ref document: EP

Kind code of ref document: A2